RIGEL PHARMACEUTICALS INC Form 8-K November 22, 2004

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 22, 2004

RIGEL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)


0-29889 (Commission File No.)

94-3248524 (IRS Employer Identification No.)

1180 Veterans Boulevard

South San Francisco, CA 94080

(Address of principal executive offices and zip code)



Item 8.01. Other Events.

On November 22, 2004, Rigel Pharmaceuticals, Inc. announced the results from its Phase I/II clinical study of R803, a novel oral hepatitis C RNA polymerase inhibitor. The press release dated November 22, 2004, titled Poor Bioavailability Results In Insignificant Clinical Effects For Rigel R803 In Phase I/II HCV Trial, is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Neither the filing of the press release as an exhibit to this Current Report on Form 8-K nor the inclusion in that press release of a reference to Rigel s internet address shall, under any circumstances, be deemed to incorporate the information available at that internet address into this Current Report on Form 8-K. The information available at Rigel s internet address is not part of this Current Report on Form 8-K or any other report filed by Rigel with the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No. Description

99.1 Press Release, dated November 22, 2004, entitled Poor Bioavailability Results In Insignificant Clinical Effects For Rigel R803 In Phase I/II HCV Trial.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RIGEL PHARMACEUTICALS, INC.

Dated: November 22, 2004

By: /s/ James H. Welch

James H. Welch

Vice President, Chief Financial Officer and Secretary

3

EXHIBIT INDEX

Exhibit No.
99.1 Press Release, dated November 22, 2004, entitled Rigel R803 In Phase I/II HCV Trial.

Description
Proor Bioavailability Results In Insignificant Clinical Effects For Rigel R803 In Phase I/II HCV Trial.

4